share_log

Moderna | 4: Statement of changes in beneficial ownership of securities-Director AFEYAN NOUBAR

Moderna | 4: Statement of changes in beneficial ownership of securities-Director AFEYAN NOUBAR

Moderna | 4：持股變動聲明-董事 AFEYAN NOUBAR
美股SEC公告 ·  06/08 07:02
牛牛AI助理已提取核心訊息
Noubar Afeyan, associated with Moderna, Inc. [MRNA], completed a series of open market sales transactions of the company's common stock on June 5, 2024. Afeyan disposed of a total of 15,000 shares at prices ranging from $145.91 to $154.86, resulting in a total market value of $2,268,803.77. Following these transactions, Afeyan directly holds 1,946,931 shares of Moderna. Additionally, indirect holdings through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc. amount to 9,666,038 shares.
Noubar Afeyan, associated with Moderna, Inc. [MRNA], completed a series of open market sales transactions of the company's common stock on June 5, 2024. Afeyan disposed of a total of 15,000 shares at prices ranging from $145.91 to $154.86, resulting in a total market value of $2,268,803.77. Following these transactions, Afeyan directly holds 1,946,931 shares of Moderna. Additionally, indirect holdings through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc. amount to 9,666,038 shares.
Noubar Afeyan是Moderna公司 [MRNA] 的關聯人，在2024年6月5日完成了一系列公司普通股的公開市場銷售交易。Afeyan總共出售了15,000股，價格在$145.91至$154.86之間，導致總市值爲$2,268,803.77。這些交易之後，Afeyan直接持有1,946,931股現代納公司股票。此外，通過Flagship Ventures Fund IV、L.P.，Flagship Ventures Fund IV-Rx、L.P.和Flagship Pioneering, Inc.的間接持有數量總計爲9,666,038股。
Noubar Afeyan是Moderna公司 [MRNA] 的關聯人，在2024年6月5日完成了一系列公司普通股的公開市場銷售交易。Afeyan總共出售了15,000股，價格在$145.91至$154.86之間，導致總市值爲$2,268,803.77。這些交易之後，Afeyan直接持有1,946,931股現代納公司股票。此外，通過Flagship Ventures Fund IV、L.P.，Flagship Ventures Fund IV-Rx、L.P.和Flagship Pioneering, Inc.的間接持有數量總計爲9,666,038股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。